Article Text

Download PDFPDF
MEK inhibition for low-grade serous ovarian cancer: are we there yet?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.


  • Twitter @marianascarant1

  • Contributors MS, MCM-M, and CG performed the literature searches. All authors contributed to manuscript writing and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests MS has received personal fees from AstraZeneca and personal fees from Merck Sharp and Dohme outside the submitted work. CG and MCM-M have nothing to disclose.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.